Reference antibody used in research and development for ophthalmology applications, particularly in the treatment of retinal diseases such as diabetic retinopathy and neovascular age-related macular degeneration (wet AMD). It functions by inhibiting platelet-derived growth factor-C (PDGF-C), which plays a role in abnormal blood vessel formation and fibrosis in the eye. By blocking PDGF-C signaling, the antibody helps reduce pathological angiogenesis and stabilizes vascular structure when used in combination with anti-VEGF therapies. This dual inhibition approach is studied to improve outcomes in patients with neovascular eye disorders by enhancing the effectiveness of anti-VEGF treatment and reducing treatment resistance.